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ABSTRACT 
Floating drugs are an effective way to lift the absorption of the drug in the stomach. Drugs made drugs last longer in the stomach so that the 
solubility process will occur effectively in the stomach. This review-journal was created by extracting indexed journals with the floating drug as 
journal keywords of 40 journals. This assessment of a floating drug for a new drug delivery system (NDDS) is established to elucidate the floating 
drugs delivery system (FDDS) based on existing literature. The most recent progress of FDDS includes the formulation and physiological variables 
that could affect gastric retention and formulation are dealt with in detail. This review also summarizes some approaches to prepare a floating 
system, evaluation methods and characterization for FDDS pharmaceutical dosage form and also its classification. 
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INTRODUCTION 
Unique of the target drug delivery systems is to reach a therapeutic 
concentration of medicine to the fix target and to ensure the optimum 
drug level [1]. Drugs that absorbed in the gastrointestinal route easily 
will dissolve quickly from the systemic circulation. If an inadequate 
drug release preparation of drug and the residence time at the upper 
gastrointestinal (a prominent place for the absorption of many drugs) 
very fast will make bioavailability become low. Thus, prolonged gastric 
maintenance is very important at the control of gastroprotection time 
to formulate a system of controlled release in the stomach for 
elongated periods of time and could be estimated [2]. Anticipation 
depends on the state of the subject and design of formulation itself, the 
maintenance activity can last from several minutes until hours (usually 
12 h). The scheme of the drug delivery system is controlled oral (DDS) 
is usually referred to get bioavailability of the drug that is more 
probable and repaired [3]. The typical drug has the development of 
oral drug delivery systems that make up of the optimization of dosage 
form and GI physiology habits [4]. Floating drug-delivery system 
(FDDS) is a gastro retentive pharmaceutical preparation that could 
delay the gastric residence time to obtain adequate bioavailability of a 
drug [5]. The system is floating in the gastric fluid for a low substance 
density than the aqueous medium [6]. 
Definition 
Floating systems are low-density systems that have sufficient 
resistance to float on the stomach and stay afloat in the gastric 
without creat? an effect on the gastric emptying rate for a long 
period time. While the system floats on the gastric contents, the 
drug will be released slowly at the desired concentration in the 
system. Thus, the residue will be cleared from the stomach. These 
results will conduct to GRT elevation and be better control of flux 
in plasma drug concentrations. Even so, furthermore, to the 
content of the stomach minimally required to enable the 
achievement of the right of retention of the principle of buoyancy, 
floating style minimal level (F) also required to give a reliable 
dosage form floats on the surface of foods [7]. It also useful for 
proximal gastrointestinal (GI) tracts local drugs, for example, 
antibiotics for Helicobacter pylori on the manage for a peptic ulcer 
[8], and for drugs that difficult to dissolve or not stable in 
intestinal fluids [9]. 
Anatomi and physiology the stomach 
Topographically, the stomach has five regions (fig. 1): (1) the cardia 
and gastroesophageal (GE) junction, (2) the fundus, (3) the antrum, 
(4), the corpus and (5) the pylorus. 
 
 
Fig. 1: Structure of gasrtics [10] 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 12, Issue 4, 2020 
Sopyan et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 51-54 
52 
In the stomach, part of the proximal made by fundus. The body acts 
as a reservoir for undigested materials and the antrum is the 
principal site for mixing gestures and acts as a pump for gastric 
emptying by propelling actions [11, 12]. Gastric emptying is present 
in both the fasting and fed states' time. During the fasting state, the 
inner digestive myoelectric cycle or migrating myoelectric cycle 
(MMC) occurs during 2-3 h, which are further divided into four 
phases [13]. 
a. Period 1 (Basic phase) 
Last from 30-60 min with infrequent contractions. 
b. Period 2 (Preburst phase) 
Last for 20-40 min with recurrent action potential and contractions. 
c. Period 3 (Burst phase) 
Last for 10-20 min, which includes powerful and regular 
contractions for a short period. 
d. Period 4 
Last for 0-5 min and happens between stage 2 and 1 of 2 repeated 
cycles (fig. 2). 
 
 
Fig. 2: Gastrointestinal motility model 
 
The stomach has three layers of muscular a circular inside layer, a 
mid longitudinal layer, and an outside but incomplete oblique layer. 
Motor functions in the stomach are isolated by region. The fundus 
relaxes as fluids and solids enter the esophagus, a response known 
as accessible relaxation, and further, as food enters the funds, a 
process is known as adaptive relaxation [14, 15]. This response 
permits the liquid to pool in the fundus bag while the solid 
components of the meal remain in the mainstream of the flow to the 
pylorus. After the ingestion of a mixed meal, the pattern of 
contractions varies from fast to that of the fed state, which is also 
termed as digestive motility pattern. 
Advantages of floating drug delivery systems 
1. Tablets or capsules in the floating tablet forms will remain in the 
liquid for a prolonged time, even at the high pH of the intestine 
region. 
2. In the stomach, Floating Drug 
Delivery Systems are advantageous for local action, ex: Antacids 
3. Floating drugs delivery system dosage forms are advantageous in 
the case essential of intestinal movement and in diarrhea to keep the 
drug in the floating state in the stomach to obtain a relatively better 
response. 
4. Acidic stuffs like aspirin cause annoyance on the stomach barrier 
when coming in contact with it hence; HBS/FDDS formulations may 
be valuable for the administration of aspirin and other similar drugs. 
5. The FDDS are advantageous for drugs absorbed by the stomach 
ex: Antacids and Ferrous salts [16]. 
Disadvantages of floating drug delivery systems 
1. Floating systems are not viable for those drugs that have solubility 
or stability problems in gastric fluids. 
2. Nifedipine, which is well absorbed along the entire GI tract and 
which undertake significant first-pass metabolism, may not be 
appropriate candidates for Floating Drug Delivery Systems since the 
slow gastric clearing may cause reduced systemic bioavailability 
(BA). Also, there are limitations to the applicability of FDDS for 
drugs that are irritant to the gastric mucosa. 
3. FDDS needs a sufficiently high level of fluids in the stomach so that 
the drug dosages form float within and work efficiently. 
4. These systems also afect to the presence of food to delay their 
gastric emptying [17, 18]. 
Classification of the floating mechanism 
Floating drug delivery systems (NDDS) are characterized based on 
two varieties of preparation variables: effervescent and Non-
effervescent system such as fig. 3 
 
 
Fig. 3: Classificaction of floating system [13, 19] 
 
Non-effervescent system 
The non-effervescent FDDS primarily based on the system of 
swelling of the polymer or the adhesion to the mucosal layer of the 
gastrointestinal tract. Two of the most common excipient for non-
effervescent FDDS are gel-forming or highly swellable cellulose type 
of hydrocolloid, polysaccharides and also matrix-forming material 
such as polycarbonate, polyacrylate, polystyrene, polymethacrylate as 
well as a bio-adhesive polymer such as chitosan and carbopol [20].  
Colloidal gel barrier system 
Sheth and Tossounian original design the Hydrodynamically 
Balanced System (HBS) that contains drugs with gel-forming 
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hydrocolloid, back in 1975. The system corporation a high level of 
gel-forming around 20-75% w/w, highly swellable, cellulose type 
hydrocolloids, polysaccharides and also matrix-forming polymers. 
When coming into contact with gastric fluid, these hydrocolloids in 
the system will hydrate and forming a colloidal gel barrier around 
the surface. These gel barriers monitor the rate of penetration of the 
fluid to the device and the release of the drug [21]. 
Bilayer floating tablet 
Bilayer floating tablet contain of two-layer of immediate-release 
tablet that release the first dose of the system while the sustained 
release layer absorb the gastric fluid and form a colloidal gel barrier 
on the superficial, it preserves the bulk density to less than one and 
will remain floating in the stomach [12]. 
Micro-porous compartment system 
A Microporous section has pores placed on the top and bottom of the 
wall containing a packed medicine reservoir. The peripheral wall 
drug reservoir is completely sealed to seal the insoluble drug in the 
stomach surface. The entrapped in the room will be utilized to float 
the system on the stomach contents and into the fluid hole that will 
dissolve the drug to be absorbed in the intestine [22]. 
Alginate beads 
Multi-unit floating dosage forms are made from freeze-dried calcium 
alginate. Round beads with 2.5 mm diameter can be equipped with 
dripping sodium alginate soluble to a calcium chloride solution; this 
process will result in precipitation of calcium alginate which can 
form a porous system that can reinforce the capacity to float for 
more than 12 h and have some more time long [23]. 
Hollow microspheres 
Hollow microspheres are micro-balloons occupied with medication 
in the outer shell of the polymer and applied by the emulsion solvent 
diffusion method. Ethanol solution: aqueous dichloromethane and 
enteric solution of PVA of a turn temperature of 400 °C. The 
resulting gas phase is spread into polymer droplets by vaporization 
of dichloromethane, forming an internal hollow in a polymeric 
microsphere with the drug formed an internal cavity in the 
microsphere of polymer with the drug. The micro balloons will float 
constantly over the surface of acidic dissolution media that keep a 
surfactant for more than 12 h (in vitro) [24]. 
Effervescent system 
In an effervescent system, preparation is designed to produce 
carbon dioxide gas. Among them are carbonates, generating gas, and 
other organic acids. The design of the formulation is intended to 
decrease the density system that can be floating in the gastric fluid 
[25]. The free CO2 gas can mix rapidly in the tablet matrix in the case 
of single-layered tablets [17]. The other way is through combining a 
matrix that contains a part of liquid, were later from the fusion, will 
produce gas that will evaporate at body temperature [26]. This 
effervescent system can be categorized into two groups, gas-
producing system and volatile liquid containing the system. 
Volatile liquid 
The volatile liquid containing systems Inflatable chamber with a liquid 
can be included which provides sustained gastric retention of the drug 
delivery system [27]. Liquids in this system include cyclopentane, 
either that gasifies at body temperature, which can result in 
inflammation of the chamber in the stomach. They contain a 
deformable hollow unit which osmotically controls floating systems. 
The system is differed into two compartments; the first section 
contains a drug and there is a volatile liquid in the second 
compartment [28]. It contains polymers that gasify at body 
temperatures effervescent compounds such as swellable polymers like 
methodical and polysaccharides tartaric acid, sodium bicarbonate, and 
citric acid. Resin beads loaded with bicarbonate and coated with 
ethylcellulose are the most common approach for the preparation of 
these systems. The ethylcellulose coating is permeable to water, which 
releases CO2 owing to which it floats [29]. 
Raft forming systems 
Raft forming systems consume a fundamental mechanism by 
forming a thick interconnected gel in contact with gastric fluid, in 
which apiece part of the portion of the liquid forms a continuous 
layer called a raft. The formation of carbon dioxide gas can take this 
raft afloat. Also, carbon dioxide can avoid the discharge of gastric 
fluid into the esophagus [30]. This system usually contains a gelling 
agent, a carbonate or a bicarbonate base to make a less dense system 
and can make it float in the gastric solution [31]. 
Factors affecting gastric retention time of the preparation 
1. Density-should be lower than that of the gastric fluidal contents 
(1.004 g/ml) 
2. Size-the diameter of more than 7.5 mm [32]. 
3. Incidence of feeding-GRT can rise by more than 400 min when 
consecutive foods are dispense compared to a single meal due to 
low-frequency MMC. 
4. Caloric content can be increased by 4-10 with foods high in 
protein and fat. 
5. Gender-average outpatient GRT in men (3.4 h) less than age and 
race matching with women (4.6 h) regardless of height, body weight 
and surface [33]. 
Evaluation of floating tablet 
Drug content 
Five tablets for each group were taken and ground. The powder 
equal to 100 mg of the drug was weighed and moved to a beaker 
glass and then 0.01 N HCl was added and then shaken for 5 min and 
added 0.01 N HCl to make up to 100 ml and the solution was then 
produced for 15 min and filtered through the filter paper Whatman. 
Finally, a solution was diluted appropriately and then measured 
spectrophotometrically at 203 nanometers using a UV-Visible 
spectrophotometer (Jasco V530 with 0.01N HCl blank) [34]. 
Hardness 
Tablets are sited between two anvils of hardness tester and the force 
(kg) is slowly increased to get a proper reading. Readings on a 
noticeable scale are recorded for the pressure, which is required to 
break the tablet [35]. 
Determination of the drug content uniformity 
The portion of drug content provides how much volume of drug is in 
the formulation. It should not exceed the limits obtained by standard 
monographs. The drug content is determined using HPLC, NIRS, 
HPTLC, Microtitrimetric method, and ICPAES [36]. 
Swelling index 
The swelling behavior of the measuring unit is determined by the 
weight assignment. The tablet swelling index corresponds to the 
tablet site in the dissolution tool basket (type 1) using a pH 6.8 
buffer dissolution medium at 37±0.5 °C. The trials were conducted in 
triplicate for each time point; the swelling index was calculated 
using the following formula [37]. 
Test of disintegration time  
The time of tablet disintegration was carried out by using a 
terminate tablet disintegration test device [38]. 
Floating properties 
The effect of formulation variables on the floating properties of 
gastric drug delivery systems is determined by using a continuous 
floating monitoring system and statistical trial design [32, 38]. 
In vitro dissolution studies 
The rate of release of ondansetron hydrochloride from floating 
tablets is established using the USP Dissolution Testing Apparatus 2 
(paddle method). The dissolution test was made using 900 ml 0.1 N 
HCl for 12 h. The sample (5 ml) of the solution was quite from the 
dissolution apparatus every hour and the sample was changed with 
a new dissolution medium. The sample was filtered through a 0.45μ 
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membrane filters and diluted to a concentration corresponding to 
0.1 N HCl for 12 h. The transmitter or absorbance of this solution 
was quantified at 310 nm [37, 39, 40]. 
CONCLUSION 
Drugs with poor absorption rates in intestinal pH can be repaired 
using the FDDS approach. The strategy of making FDDS varies 
greatly depending on the physicochemical nature of the drug and the 
systematic approach that makes the drug last long in the stomach. 
The FDDT can be achieved by a non-effervescent system, colloidal 
gel barrier system, bilayer floating tablet, micro-porous 
compartment system, alginate beads, hollow microspheres 
effervescent system, volatile liquid, and raft forming systems and it 
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